News
TENX
1.870
+0.54%
0.010
Tenax pauses Phase 3 levosimendan trial to refine criteria
TipRanks · 2d ago
Tenax Therapeutics Temporarily Pauses Enrollment In LEVEL-2 Trial Of TNX-103 To Amend Criteria; Requests FDA Meeting
Benzinga · 2d ago
Weekly Report: what happened at TENX last week (0928-1002)?
Weekly Report · 5d ago
Weekly Report: what happened at TENX last week (0921-0925)?
Weekly Report · 09/28 09:56
Monday 9/21 Insider Buying Report: TH, TENX
NASDAQ · 09/21 17:36
Weekly Report: what happened at TENX last week (0914-0918)?
Weekly Report · 09/21 09:57
Piper Sandler Remains a Buy on Tenax Therapeutics (TENX)
TipRanks · 09/15 11:45
Weekly Report: what happened at TENX last week (0907-0911)?
Weekly Report · 09/14 10:00
Tenax Therapeutics Updates Phase 3 LEVEL Trial Strategy
TipRanks · 09/09 12:41
Weekly Report: what happened at TENX last week (0831-0904)?
Weekly Report · 09/07 09:55
Major Investment Firm Quietly Makes Bold Move Into Tenax Therapeutics
TipRanks · 09/03 02:07
Analyst Maintains Buy on Tenax Therapeutics as Subgroup Data Support Drug’s Potential; Price Target Reiterated at $4
TipRanks · 09/01 12:36
5 Stocks In The Spotlight From Wall Street's Most Accurate Analysts Last Month
Benzinga · 09/01 07:27
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 08/31 17:06
Midday Fly By: Aon buying USI, Lilly to acquire Merida
TipRanks · 08/31 16:01
Deere upgraded, Lumentum initiated: Wall Street’s top analyst calls
TipRanks · 08/31 13:50
This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Benzinga · 08/31 13:18
Tenax Therapeutics Cut to Neutral From Buy by Guggenheim
Dow Jones · 08/31 13:06
Guggenheim Downgrades Tenax Therapeutics to Neutral
Benzinga · 08/31 12:55
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
TipRanks · 08/31 11:20
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).